{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.42","value":"1516"},{"groupId":"OG001","spread":"37.13","value":"1352"},{"groupId":"OG002","spread":"34.05","value":"1426"},{"groupId":"OG003","spread":"32.65","value":"1303"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.40","value":"118.3"},{"groupId":"OG001","spread":"36.98","value":"99.73"},{"groupId":"OG002","spread":"35.04","value":"108.0"},{"groupId":"OG003","spread":"28.26","value":"96.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: N-desmethyl selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.55","value":"2412"},{"groupId":"OG001","spread":"48.14","value":"1672"},{"groupId":"OG002","spread":"49.40","value":"2021"},{"groupId":"OG003","spread":"31.40","value":"1630"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.30","value":"145.6"},{"groupId":"OG001","spread":"35.17","value":"102.4"},{"groupId":"OG002","spread":"37.71","value":"122.8"},{"groupId":"OG003","spread":"14.43","value":"113.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: N-desmethyl selumetinib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4 and 6 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1). Pre-dose, 1, 2, 3, 4 and 6 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib and N-desmethyl Selumetinib AUC0-6 Derived After Single and Multiple Dose Administration","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}